SkylineDx Highlights Merlin Assay's Power to Predict Recurrence Risk of Head and Neck Melanoma Without Sentinel lymph node Biopsy at ASCO 2025

SkylineDx United States of America United Kingdom Netherlands

Merlin accurately identifies patients with head and neck melanoma at high risk of recurrence, even without sentinel lymph node biopsyStudy reveals that patients with CP-GEP High-Risk are over seven times more likely to have a recurrence and 10 times more likely to die from melanoma, compared to patients with CP-GEP Low-RiskView original content:https://www.prnewswire.co.uk/news-releases/skylinedx-highlights-merlin-assays-power-to-predict-recurrence-risk-of-head-and-neck-melanoma-without-sentinel-lymph-node-biopsy-at-asco-2025-302470645.html